Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Gamma PN3
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Gamma PN3 in the Elderly
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 20, 2024
Lead Product(s) : Gamma PN3
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gamma-PN3
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GPN Reports Positive Safety and Immunogenicity Data from Phase 1 Trial of Gamma-PN
Details : Gamma-PN3 is a non-adjuvanted whole cell-pneumococcal vaccine. It is under phase 1/2 clinical development for the treatment of Pneumococcal Infections.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 01, 2024
Lead Product(s) : Gamma-PN3
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gamma-PN3
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Extension Safety and Immunogenicity Study of GPNV-001
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 08, 2023
Lead Product(s) : Gamma-PN3
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gamma-PN3
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : BioCina
Deal Size : Undisclosed
Deal Type : Partnership
BioCina Expands Partnership with GPN Vaccines
Details : Under the agreement, BioCina will manufacture large-scale cGMP batches for proprietary engineered whole-cell vaccine called Gamma-PN3 against Streptococcus pneumoniae.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 11, 2023
Lead Product(s) : Gamma-PN3
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : BioCina
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Gamma-PN3
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
December 29, 2022
Lead Product(s) : Gamma-PN3
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable